9 items · search:live+archive
Daily average lexicon sentiment across 202 scored headlines over the last 8 days. For market-wide mood (VIX, breadth, regime), see Markets. For the learned model that predicts forward return from a headline, see Headline Forecast Model.
enGene Therapeutics Inc. (ENGN) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 7:00 AM EDTCompany ParticipantsRonald H.
enGene Therapeutics trades below cash value. Read on to assess risks, cost cuts extending the runway to 2029, and the potential upside to a $6.65 fair value.
Citizens analyst Silvan Turkcan reiterates enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Market Perform.
BOSTON & MONTREAL, September 08, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates.
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 17.54 percent increase over losses of $(0.57) per share from
BOSTON & MONTREAL, September 01, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences:
enGene (NASDAQ:ENGN) outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystecto
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer August 11, 2026 11:00 AM EDTCompany...
2026-08-11. The following slide deck was published by enGene Therapeutics Inc.